Calcium, cyclic AMP, and MAP kinases: dysregulation in polycystic kidney disease.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 18195694.
- Also identified by DOI 10.1038/sj.ki.5002695.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Low intracellular calcium, present in untreated polycystic kidney epithelia, results in a proliferative response to cyclic adenosine monophosphate. Treatment with a calcium channel blocker (CCB) caused exacerbation of autosomal dominant polycystic kidney disease in rats. Data regarding use of CCBs in human polycystic kidney disease (PKD) are limited and mixed. Thus, it is premature to extrapolate these findings to human PKD.
Medical subject headings
- Calcium Channel Blockers
- Cell Proliferation
- Kidney
- Polycystic Kidney Diseases
- Verapamil